Elpiscience BioPharma and Bio-Techne Corp. have entered into a strategic collaboration for the development of anti-cancer therapeutics. Elpiscience will have access to multiple antibodies from Bio-Techne’s product portfolio for use in the development of preclinical, clinical, and commercial biopharmaceuticals.

Elpiscience is developing next generation cancer immunotherapies, and Bio-Techne, a global provider of molecular diagnostics, aim to expand mutual capabilities under the alliance in the field of cancer immunotherapy. This collaboration also aims to accelerate the development of new biologics to address unmet medical needs in oncology.

Dr. Darren Ji, chief executive officer of Elpiscience, said, “We are very happy to enter into a strategic collaboration with Bio-Techne in therapeutic antibody research and development. This collaboration will leverage the strengths of both companies in the field of anti-cancer therapeutics and speed up the development of new cancer immunotherapies in order to bring more efficient treatment to cancer patients worldwide.”

David Eansor, president of Bio-Techne’s Protein Sciences Segment commented, “We are extremely excited to partner with Elpiscience for the development of novel cancer immunotherapies. It is our goal to increase our partnerships with developers of therapeutics in order to unleash the potential of our vast library of high-quality antibodies towards the development of next generation immunotherapies.”